XML 99 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
SEGMENT INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2013
Segment Reporting [Abstract]  
Schedule of segment revenues and profit
Segment revenues and (loss) profit for the three-month and nine-month periods ended September 30, 2013 and 2012 were as follows:
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2013
 
2012
 
2013
 
2012
Revenues:
 
 
 
 
 
 
 
Developed Markets(1)
$
1,142,712

 
$
647,194

 
$
2,722,834

 
$
1,860,833

Emerging Markets(2)
399,019

 
236,946

 
983,014

 
699,500

Total revenues
1,541,731

 
884,140

 
3,705,848

 
2,560,333

 
 
 
 
 
 
 
 
Segment (loss) profit:
 
 
 
 
 
 
 
Developed Markets(3)
(328,610
)
 
242,314

 
106,316

 
610,274

Emerging Markets(4)
19,524

 
18,800

 
63,906

 
61,258

Total segment (loss) profit
(309,086
)
 
261,114

 
170,222

 
671,532

 
 
 
 
 
 
 
 
Corporate(5)
(39,285
)
 
(33,243
)
 
(129,760
)
 
(102,727
)
Restructuring, integration and other costs
(295,890
)
 
(42,872
)
 
(398,540
)
 
(135,213
)
In-process research and development impairments and other charges
(123,981
)
 
(145,300
)
 
(128,811
)
 
(149,868
)
Acquisition-related costs
(8,650
)
 
(4,605
)
 
(24,428
)
 
(25,977
)
Legal settlements and related fees
(149,601
)
 
—

 
(155,173
)
 
(56,779
)
Acquisition-related contingent consideration
34,995

 
(5,630
)
 
33,511

 
(23,198
)
Operating (loss) income
(891,498
)
 
29,464

 
(632,979
)
 
177,770

Interest income
2,686

 
1,156

 
5,336

 
3,299

Interest expense
(249,306
)
 
(116,042
)
 
(581,414
)
 
(318,681
)
Loss on extinguishment of debt
(8,161
)
 
(2,322
)
 
(29,540
)
 
(2,455
)
Foreign exchange and other
5,079

 
(1,603
)
 
(3,564
)
 
18,458

Gain on investments, net
—

 
—

 
5,822

 
2,024

Loss before recovery of income taxes
$
(1,141,200
)
 
$
(89,347
)
 
$
(1,236,339
)
 
$
(119,585
)
____________________________________
(1)
Developed Markets segment revenues reflect incremental product sales revenue of $620.4 million and $1,154.3 million, in the aggregate, from all 2012 acquisitions and all 2013 acquisitions in the three-month and nine-month periods ended September 30, 2013, respectively, primarily from the Medicis, B&L, Obagi, OraPharma, Eisai, J&J North America and QLT acquisitions.
(2)
Emerging Markets segment revenues reflect incremental product sales revenue of $136.8 million and $212.1 million, in the aggregate, from all 2012 acquisitions and all 2013 acquisitions in the three-month and nine-month periods ended September 30, 2013, respectively, primarily from the B&L, Natur Produkt, Gerot Lannach and Atlantis acquisitions.
(3)
Developed Markets segment (loss) profit reflects (i) the addition of operations from all 2012 acquisitions and all 2013 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $339.6 million and $740.6 million, in the aggregate, in the three-month and nine-month periods ended September 30, 2013, respectively, primarily from legacy Valeant, Medicis and B&L operations and (ii) an impairment charge of $551.6 million related to ezogabine/retigabine in the third quarter of 2013 (see note 7 titled “FAIR VALUE MEASUREMENTS”).
(4)
Emerging Markets segment profit reflects the addition of operations from all 2012 acquisitions and all 2013 acquisitions, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $95.9 million and $210.2 million, in the aggregate, in the three-month and nine-month periods ended September 30, 2013, respectively, primarily from B&L, legacy Valeant and Medicis operations.
(5)
Corporate reflects non-restructuring-related share-based compensation expense of $16.0 million and $32.5 million in the three-month and nine-month periods ended September 30, 2013, respectively, compared with $18.5 million and $52.9 million in the corresponding periods of 2012.
Schedule of total assets by segment
Total assets by segment as of September 30, 2013 and December 31, 2012 were as follows:
 
As of
September 30,
2013
 
As of
December 31,
2012
Assets:
 
 
 
Developed Markets(1)
$
20,774,549

 
$
12,893,726

Emerging Markets(2)
6,502,205

 
4,022,039

 
27,276,754

 
16,915,765

Corporate
927,630

 
1,034,614

Total assets
$
28,204,384

 
$
17,950,379

____________________________________
(1)
Developed Markets segment assets as of September 30, 2013 reflect (i) the provisional amounts of identifiable intangible assets and goodwill of B&L of $3,945.0 million and $3,271.6 million, respectively, (ii) the amounts of identifiable intangible assets and goodwill of Obagi of $335.5 million and $158.5 million, respectively, and (iii) the amounts of identifiable intangible assets acquired from Eisai of $112.0 million.
(2)
Emerging Markets segment assets as of September 30, 2013 reflect (i) the provisional amounts of identifiable intangible assets and goodwill of B&L of $769.2 million and $1,116.4 million, respectively, (ii) the provisional amounts of identifiable intangible assets and goodwill of Natur Produkt of $98.8 million and $34.7 million, respectively, and (iii) the amount of Obagi’s goodwill of $21.6 million.